



# SPAFID CONNECT

Informazione Regolamentata n. 0472-29-2019	Data/Ora Ricezione 19 Luglio 2019 09:29:37	MTA - Star
--	--	------------

Societa' : BB BIOTECH

Identificativo : 120825

Informazione  
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : 1.2

Data/Ora Ricezione : 19 Luglio 2019 09:29:37

Data/Ora Inizio : 19 Luglio 2019 09:29:38

Diffusione presunta

Oggetto : BB Biotech AG publishes its interim report

*Testo del comunicato*

Vedi allegato.

Media release of July 19, 2019

Interim report of BB Biotech AG as at June 30, 2019

## **BB Biotech AG publishes its interim report**

BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2019, which covers the results of its business activities for the first six months of 2019.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2019 amounted to CHF 554 mn (loss of CHF 70 mn in H1 2018). For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at June 30, 2019 can be downloaded at [www.bbbiotech.com](http://www.bbbiotech.com).

### **For further information:**

#### **Investor Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00  
Dr. Silvia Siegfried-Schanz, [ssc@bellevue.ch](mailto:ssc@bellevue.ch)  
Maria-Grazia Iten-Alderuccio, [mga@bellevue.ch](mailto:mga@bellevue.ch)  
Claude Mikkelsen, [cmi@bellevue.ch](mailto:cmi@bellevue.ch)

#### **Media Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00  
Tanja Chicherio, [tch@bellevue.ch](mailto:tch@bellevue.ch)

TE Communications AG, Bleichstrasse 11, 9000 St. Gallen, Switzerland, Tel. +41 79 423 22 28  
Thomas Egger, [teg@te-communications.ch](mailto:teg@te-communications.ch)

#### **[www.bbbiotech.com](http://www.bbbiotech.com)**

#### **Company profile**

BB Biotech AG invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech AG is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech AG's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

#### **Disclaimer**

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech AG, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech AG and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech AG and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Fine Comunicato n.0472-29

Numero di Pagine: 3